Advertisement
Research Article| Volume 33, ISSUE 8, P673-678, October 2002

Cimetidine prevents suppression of delayed hypersensitivity in an animal model of haemorrhagic shock

      Abstract

      Background: Cimetidine reverses immunosuppression following trauma, however, its effect on pure haemorrhagic shock is unknown. Methods: Mice sensitized by injection of sheep red blood cells (SRBCs), were subjected to cardiac puncture and randomized to a control group-A (n=11) and three shock groups (35% of blood volume extracted): group-S had no treatment (n=16), group-CP received cimetidine 50 mg/kg intraperitoneally (n=16), group-CW received oral cimetidine (200 mg/kg per day, n=16). After 5 days, animals were challenged by injection of SRBCs into the foot-pad of the right hind paw (same volume of saline was injected into left paw). Foot-pad thickness ratios (FPTRs) were determined at 16 and 40 h, and inflammatory response was assessed histologically. Results: At 16 h, FPTRs were greater in group-CW than group-S (P=0.01). There were no differences at 40 h. More animals in groups-CP and -CW had grade 3/4 inflammation, whilst group-S had the least inflammatory response (NS). Conclusions: Cimetidine prevents suppression of delayed hypersensitivity in this model.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Injury
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Ayala A.
        • Lehman D.L.
        • Herdon C.D.
        • Chaudry I.H.
        Mechanism of enhanced susceptibility to sepsis following haemorrhage.
        Arch. Surg. 1994; 129: 1172-1178
        • Hansbrough J.
        • Peterson V.
        • Zapata-Sirvent R.L.
        • Claman H.N.
        Postburn immunosuppression in an animal model. II. Restoration of cell-mediated immunity by immunomodulating drugs.
        Surgery. 1984; 95: 290-295
        • Miller S.E.
        • Miller C.L.
        • Trunkey D.D.
        The immune consequences of trauma.
        Surg. Clin. North Am. 1982; 62: 167-181
        • Baker C.C.
        • Oppenheimer L.
        • Stephens B.
        • Lewis F.R.
        • Trunkey D.D.
        Epidemiology of trauma deaths.
        Am. J. Surg. 1980; 140: 144-150
        • Esrig B.C.
        • Frazee L.
        • Stephenson S.F.
        • Fulton R.L.
        • Jones C.E.
        Predisposition to infection and neutrophil function following haemorrhagic shock.
        Rev. Surg. 1976; 33: 431-433
        • Stephan R.N.
        • Kupper T.S.
        • Geha A.S.
        • Baue A.E.
        • Chaudry I.H.
        Haemorrhage without tissue trauma produces immunosuppression and enhances susceptibility to sepsis.
        Arch. Surg. 1987; 122: 62-68
        • Chang Y.H.
        • Jagels M.
        • Abraham E.
        Haemorrhage produces depressions in alloantigen-specific immune responses in the mouse through activation of suppressor T cells.
        Clin. Exp. Immunol. 1990; 80: 478-483
        • Abraham E.
        • Freitas A.A.
        Haemorrhage produces abnormalities in lymphocyte function and lymphokine generation.
        J. Immunol. 1989; 142: 899-906
        • Livingston D.H.
        Interferon-γ reverses bone marrow inhibition following haemorrhagic shock.
        Arch. Surg. 1991; 126: 100-103
        • Nielsen H.J.
        • Nielsen H.
        • Jensen S.
        • Moesgaard F.
        Ranitidine improves postoperative monocyte and neutrophil function.
        Arch. Surg. 1994; 129: 309-315
        • Sedman P.C.
        • Ramsden C.W.
        • Brenan T.G.
        • et al.
        Effects of low dose perioperative interferon on the surgically induced suppression of antitumor immune responses.
        Br. J. Surg. 1988; 75: 976-981
        • Nielsen H.J.
        • Witt K.
        • Moesgaard F.
        • Kehlet H.
        Ranitidine for prevention of postoperative suppression of delayed hypersensitivity.
        Am. J. Surg. 1989; 157: 291-294
        • Nielsen H.J.
        • Witt K.
        • Moesgaard F.
        • Kehlet H.
        Ranitidine for improvement of delayed hypersensitivity response in patients with sepsis.
        Acta Chir. Scand. 1989; 155: 445-449
        • Nielsen H.J.
        • Hammer J.H.
        • Moesgaard F.
        • Kehlet H.
        Ranitidine prevents postoperative transfusion-induced depression of delayed hypersensitivity.
        Surgery. 1989; 105: 711-717
        • Leeper-Woodford S.K.
        • Carey D.
        • Byrne K.
        • et al.
        Histamine receptor antagonists, cyclooxygenase blockade, and tumor necrosis factor during acute septic insult.
        Shock. 1998; 9: 89-94
        • Lennard T.W.J.
        • Shenton B.K.
        • Borzotta A.
        • et al.
        The influence of surgical operations on components of the human immune system.
        Br. J. Surg. 1985; 72: 771-776
        • Baigrie R.J.
        • Lamont P.M.
        • Kwiatkowski D.
        • Dallman M.J.
        • Morris P.J.
        Systemic cytokine response after major surgery.
        Br. J. Surg. 1992; 79: 757-760
        • Christou N.V.
        • Meakins J.L.
        • Gordon J.
        • et al.
        The delayed hypersensitivity response and host resistance in surgical patients.
        Ann. Surg. 1995; 222: 534-548
        • Hall J.M.
        • Hallett C.
        A simple precise method for measuring rodent paw volume.
        J. Pharm. Pharmacol. 1975; 27: 623
        • Johnson K.B.
        • Charya R.V.
        • Atkins J.L.
        • Wiesmann W.P.
        • Pearce F.J.
        The role of histamine in mediating the decompensatory phase of haemorrhagic shock in the rat.
        Shock. 1997; 8: 444-449
        • Griswold D.E.
        • Alessi S.
        • Badger A.M.
        • Poste G.
        • Hanna N.
        Inhibition of T suppressor cell expression by histamine type 2 (H2) receptor antagonists.
        J. Immunol. 1984; 132: 3054-3057
        • Birch R.E.
        • Polmar S.H.
        Pharmacological modification of immunoregulatory T lymphocytes. I. Effect of adenosine.
        Clin. Exp. Immunol. 1982; 48: 218-230
        • Rocklin R.E.
        Histamine-induced suppressor factor (HSF): effect on migration inhibitory factor (MIF) production and proliferation.
        J. Immunol. 1977; 118: 1734-1738
        • Rezai A.R.
        • Salazar-Gonzalez J.F.
        • Martinez-Maza O.
        • Bramhall J.
        • Afrasiabi R.
        • Kermani-Arab V.
        Histamine blocks interleukin 2 (IL2) gene expression and regulates IL2 receptor expression.
        Immunopharmacol. Immunotoxicol. 1990; 12: 345-362
        • Schnaper H.W.
        • Aune T.M.
        • Roby R.K.
        A role for histamine type II (H-2) receptor binding in production of the lymphokine, soluble immune response suppressor (SIRS).
        J. Immunol. 1987; 139: 1185-1190
        • Suzuki S.
        • Huchet R.
        Properties of histamine-induced suppressor factor in the regulation of lymphocyte response to PHA in mice.
        Cell Immunol. 1982; 68: 349-358
        • Rocklin R.E.
        • Blidy A.
        • Kamal M.
        Physiochemical characterization of human histamine-induced suppressor factor.
        Cell Immunol. 1983; 76: 243-252
        • Dohlsten M.
        • Sjogren H.O.
        • Carlson R.
        Histamine inhibits interferon-γ production via suppression of interleukin-2 synthesis.
        Cell Immunol. 1986; 39: 493-501
        • Gifford R.R.
        • Tilberg A.F.
        Histamine type-2 receptor antagonist immune modulation. II. Cimetidine and ranitidine increase interleukin-2 production.
        Surgery. 1987; 102: 242-247
        • Hansbrough J.F.
        • Zapata-Sirvent R.L.
        • Bender E.M.
        Prevention of alterations in postoperative lymphocyte subpopulations by cimetidine and ibuprofen.
        Am. J. Surg. 1986; 151: 249-255
        • Zapata-Sirvent R.L.
        • Hansbrough J.F.
        Postburn immunosuppression in an animal model. III. Maintenance of normal splenic helper and suppressor lymphocyte subpopulations by immunomodulating drugs.
        Surgery. 1985; 97: 721-727
        • Adams W.J.
        • Lawson J.A.
        • Morris D.L.
        Cimetidine inhibits in vivo growth of human colon cancer and reverses histamine stimulated in vitro and in vivo growth.
        Gut. 1994; 35: 1632-1636
        • Kelly M.D.
        • King J.
        • Cherian M.
        • et al.
        Randomized trial of preoperative cimetidine in patients with colorectal carcinoma with quantitative assessment of tumor-associated lymphocytes.
        Cancer. 1999; 85: 1658-1663
        • Adams W.J.
        • Morris D.L.
        Pilot study—cimetidine enhances lymphocyte infiltration of human colorectal carcinoma.
        Cancer. 1997; 80: 15-21
        • Zapata-Sirvent R.L.
        • Hansbrough J.F.
        • Bender E.M.
        • Bartle E.J.
        • Mansour A.
        • Carter W.H.
        Postburn immunosuppression in an animal model. IV. Improved resistance to septic challenge with immunomodulating drugs.
        Surgery. 1986; 99: 53-59
        • Stewart R.M.
        • Fabian T.C.
        • Fabian M.J.
        • et al.
        Gastric and extragastric actions of the histamine antagonist ranitidine during posttraumatic sepsis.
        Surgery. 1995; 117: 68-82
        • Vial T.
        • Goubier C.
        • Bergeret A.
        • Cabrera F.
        • Evreaux J.C.
        • Descotes J.
        Side effects of ranitidine.
        Drug Saf. 1991; 6: 94-117